ReviewBiomaterials research2026
Drug Delivery Systems Repurposing Taxanes as Antitumor Immune Modulators.
Review in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Taxane chemotherapeutics, including paclitaxel, docetaxel, and cabazitaxel, are commonly used in cancer therapy because of their cytotoxic effects against malignant cells. Although their primary mechanisms involve microtubule stabilization and induction of apoptosis, emerging evidence suggests that taxanes also modulate antitumor immunity. Drug delivery systems (DDSs) have been used to enhance taxane therapeutic efficacy by improving tumor targeting and immune modulation. This review discusses the immunomodulatory effects of taxanes and their effects on spatially distinct immune processes within tumors and draining lymph nodes. We highlight recent advances in taxane DDSs that facilitate tumor- and lymphatic-targeted delivery, thereby enhancing antigen presentation, adaptive immune activation, and systemic antitumor immunity. Furthermore, we explore synergistic strategies that combined taxane-based DDSs with immune checkpoint inhibitors and other immunotherapeutic agents. By integrating these approaches, taxane-based chemoimmunotherapy presents potential for advancing next-generation cancer immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.